CFT1946
- Generic Name
- CFT1946
A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors
Phase 1
Active, not recruiting
- Conditions
- Solid TumorsMelanomaNSCLCCRCATC
- Interventions
- First Posted Date
- 2022-12-30
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- C4 Therapeutics, Inc.
- Target Recruit Count
- 89
- Registration Number
- NCT05668585
- Locations
- 🇫🇷
Chu de Lille, Lille, France
🇫🇷Institut Bergonie, Bordeaux Cedex, France
🇺🇸University of Arizona - Cancer Center, Tucson, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath